Press Releases

Access archived Guidant press releases

Access archived BTG press releases

Advanced Search
  • Dec 2, 2020
    Boston Scientific Receives FDA Approval for WaveWriter Alpha™ Spinal Cord Stimulator Systems

    MARLBOROUGH, Mass., December 2, 2020 – Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator...

  • Dec 1, 2020
    Boston Scientific Signs Definitive Agreement to Divest BTG Specialty Pharmaceuticals Business

    Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L., and SERB SAS, affiliates of SERB, a European...

  • Nov 23, 2020
    Boston Scientific to Participate in Evercore ISI 2020 Healthcare Conference

    Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1. Mike Mahoney, chairman and chief executive officer, and Susie...

  • Nov 17, 2020
    Boston Scientific Announces LOTUS Edge™ Aortic Valve System Voluntary Recall and Product Discontinuation

    Boston Scientific Corporation (NYSE: BSX) has announced it has initiated a global, voluntary recall of all unused inventory of the LOTUS Edge™ Aortic Valve System due to complexities associated...

  • Nov 5, 2020
    Boston Scientific Announces November 2020 Conference Schedule

    Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On November 12, 2020, Meghan Scanlon, senior vice president and president, Urology and...

  • Nov 2, 2020
    Boston Scientific Receives FDA Approval for the Ranger™ Drug-Coated Balloon
    Company provides physicians with first portfolio comprised of drug-eluting stent and drug-coated balloon for the treatment of patients with peripheral artery disease

    Boston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, developed for the treatment of patients with...

  • Oct 29, 2020
    Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX™ Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke
    Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation

    Boston Scientific Corporation (NYSE: BSX) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device within...

  • Oct 28, 2020
    Boston Scientific Announces Results For Third Quarter 2020

    Boston Scientific Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1.8) percent on a reported basis, (2.5) percent on an...

  • Oct 1, 2020
    Boston Scientific Announces Transcatheter Cardiovascular Therapeutics 2020 Investor Update and Conference Call Discussing Third Quarter 2020 Results

    Boston Scientific Corporation (NYSE: BSX) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) on Thursday, October 15 from 1:00 – 2:00 p.m. EDT....

  • Sep 30, 2020
    Boston Scientific Launches WaveWriter Alpha™ Spinal Cord Stimulator Systems In Europe
    SCS portfolio features full-body MRI conditional devices that combine therapy options for personalized pain relief

    Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The portfolio, consisting of four MRI conditionali,...

Show 5102550100 per page
Top